Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Garenoxacin - FUJIFILM Toyama Chemical

X
Drug Profile

Garenoxacin - FUJIFILM Toyama Chemical

Alternative Names: BMS-284756; Des-F(6)-quinolone; Desquinolone; Garenoxacin mesilate hydrate; Garenoxacin mesylate; Geninax; Inforce; T-3811; T-3811-ME

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taisho Pharmaceutical; Toyama Chemical
  • Developer FUJIFILM Toyama Chemical; Merck & Co; Taisho Pharmaceutical; Toyama Chemical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Gram-positive infections; Otorhinolaryngological infections; Respiratory tract infections
  • No development reported Bacterial infections
  • Discontinued Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Intra-abdominal infections; Skin and soft tissue infections

Most Recent Events

  • 25 Jul 2019 Registered for Respiratory tract infections in China (PO)
  • 25 Jul 2019 Fujifilm Toyama Chemical and Shenzhen Main Luck Pharmaceuticals plans to launch for Respiratory tract infections in China by March 2021
  • 25 Jul 2019 The National Medical Products Administration (NMPA) issues an imported drug license for garenoxacin for the treatment of Respiratory tract infections in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top